Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants

Medicine & Life Sciences

• Glucagon-Like Peptide 1 100%
• Bile Acids and Salts 88%
• Type 2 Diabetes Mellitus 64%
• Incretins 50%
• Glucose 39%
• Glucosidases 23%
• G-Protein-Coupled Receptors 23%
• Dipeptidyl-Peptidase IV Inhibitors 20%
• Glucagon-Like Peptide-1 Receptor 20%
• Peroxisome Proliferator-Activated Receptors 18%
• AR 231453 16%
• Metformin 16%
• 6alpha-ethyl-23(S)-methylcholic acid 15%
• cholebine 15%
• colestimide 15%
• Insulin Secretion 15%
• Colesevelam Hydrochloride 13%
• Insulin Resistance 12%
• Enteroendocrine Cells 11%
• Insulin 10%
• Dipeptidyl Peptidase 4 10%
• Peptides 9%
• Hormones 5%
• Therapeutics 5%
• Liver 3%